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Abstract: Water-pipe smoking (WPS) is becoming the most popular form of tobacco use among
the youth, especially in the Middle East, replacing cigarettes rapidly and becoming a major risk of
tobacco addiction worldwide. Smoke from WPS contains similar toxins as those present in cigarette
smoke and is linked directly with different types of cancers including lung and head and neck (HN)
carcinomas. However, the underlying molecular pathways and/or target genes responsible for the
carcinogenic process are still unknown. In this study, human normal oral epithelial (HNOE) cells,
NanoString PanCancer Pathways panel of 770 gene transcripts and quantitative real-time polymerase
chain reaction (qRT-PCR) analysis were applied to discover differentially expressed genes (DEG)
modulated by WPS. In silico analysis was performed to analyze the impact of these genes in HN
cancer patient’s biology and outcome. We found that WPS can induce the epithelial–mesenchymal
transition (EMT: hallmark of cancer progression) of HNOE cells. More significantly, our analysis of
NanoString revealed 23 genes deregulated under the effect of WPS, responsible for the modulation
of cell cycle, proliferation, migration/invasion, apoptosis, signal transduction, and inflammatory
response. Further analysis was performed using qRT-PCR of HNOE WPS-exposed and unexposed
cells supported the reliability of our NanoString data. Moreover, we demonstrate those DEG to be
upregulated in cancer compared with normal tissue. Using the Kaplan–Meier analysis, we observed
a significant association between WPS-deregulated genes and relapse-free survival/overall survival
in HN cancer patients. Our findings imply that WPS can modulate EMT as well as a set of genes that
are directly involved in human HN carcinogenesis, thereby affecting HN cancer patients’ survival.
Keywords: smoke; water pipe; head and neck cancers; gene dysregulation; oral epithelial cells
1. Introduction
Tobacco smoking is the most common preventable risk factor for several non-communicable
diseases, such as, cardiovascular, lung, diabetes as well as cancer, and can be considered lethal [1,2].
Widespread tobacco consumption is somewhat attributed to the variation in available consumption
methods, such as cigarettes, electronic cigarettes (E-cigarettes), cigars, and water-pipe smoking
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(WPS). Recently, global trend of tobacco smoking has started to shift towards WPS in addition to
E-cigarettes [3–5] with approximately 100 million smokers using WPS on daily basis [6], leading
to nearly 5 million deaths annually [7]. Global increase in WPS use is due to several factors
including its availability in several delectable flavors and aromas along with its association with
socializing, relaxation, and entertainment. Additional motives include peer-pressure, low-cost, fashion,
and inquisitiveness [3,8]. Interestingly, people from the Middle East and those of Middle Eastern
descent in Western countries smoke WPS, as they consider it to be a part of their culture, thus giving
rise to this trend in the Western world [9].
Smoke emanating from WPS includes toxins resembling those found in cigarettes, such as
carbon monoxide (CO), hydrocarbons, and carcinogenic polycyclic aromatic volatile aldehydes [10,11].
In comparison to a cigarette, which accounts for 500–600 mL of smoke inhalation per unit, a single WPS
session accounts for approximately 90,000 mL of smoke inhalation; making WPS 4-times higher in CO
exposure and 56-times higher in inhaled smoke volume [11]. Additionally, it has been pointed out that
nicotine concentration in plasma of individuals smoking one WPS daily is similar to those smoking 10
cigarettes a day [12,13]. Out of 300 chemical compounds, which have been identified in inhaled WPS
smoke, 82 have been labelled as “toxicants” [14,15] including polyaromatic hydrocarbons, heterocyclic
compounds, carbonylic compounds and volatile organic compounds, tar, nicotine, carbon monoxide,
nitrosamines, heavy metals, metal nanoparticles, phenolic compounds, flavoring chemicals (base
propylene glycol, glycerol, vanillin, cinnamaldehyde), and free radicals which can induce head and neck
(HN) as well as pulmonary toxicity [15,16]. Nevertheless, popular belief considers WPS less harmful
than cigarette smoking. However, research shows that both methods of tobacco consumption lead to
serious health problems including a variety of oral and systemic diseases, such as periodontal affliction,
cardiovascular, and pulmonary disorders [17–21]. On the other hand, we have previously reported
that WPS can exhibit a substantial embryotoxicity on the early stage of the normal development [22].
To date, various studies have confirmed the association between WPS and several types of human
cancers, including lung, esophageal, oral, and pancreatic carcinomas [23–25]. Chronic human exposure
to WPS smoke alters the expression of genes involved in detoxification, xenobiotic metabolism, as well
as DNA stability and repair processes, hence, increasing a susceptibility to various cancers [23,26].
We also recently demonstrated that WPS exposure can induce epithelial-mesenchymal transition
(EMT) and enhance a cell invasion ability of human breast cancer cells via the activation of Erk1/Erk2
pathways [27]. However, the exact role of WPS exposure on human cancer initiation, including HN,
is still unclear. Therefore, in the current study, we aimed to explore the role of chronic exposure to WPS
on molecular pathways and gene targets in human normal oral epithelial cells, which can increase
their susceptibility to cancer.
2. Materials and Methods
2.1. Smoking Machine Protocol and WPS Preparation
A standard smoking protocol (Aleppo Method) was used as described previously by our
group [22,27]. The water pipe was prepared by padding the head with 10 gr of brand tobacco
mixture known as “Two Apples”, covering it with aluminum foil and perforating the foil to allow air
passage. A charcoal, “Tree Kings” brand, quick-light briquette was ignited and placed on top of the
head at the beginning of the smoking session. The condensate (smoking) was collected using regular
laboratory filter paper. Filters were dried and weighed before and after collecting smoke. Subsequently,
smoked filters were solved in phosphate buffer saline (PBS) or keratinocyte serum-free media (KSFM)
(Life Technologies, Burlington, ON, Canada) with final concentration of 20 mg/mL of smoking particles;
followed by filtering PBS or KSFM solutions using 0.45µm filters (Costar, Washington, DC, USA).
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2.2. Cell Lines
Two human normal oral epithelial (NOE) cell lines established in our laboratory [28] were used
and maintained at 37 ◦C in a humidified atmosphere of 5% CO2 in air. The cells were cultured in
KSFM with 5 mg/100 mL of bovine pituitary extract (BPE) (Life Technologies, Burlington, ON, Canada),
and 100 µg/mL penicillin–streptomycin. Cells were treated either with 100 µg/mL of WPS in PBS or
KSFM solution for 48 h.
2.3. RNA Extraction and Reverse Transcriptase Real-Time PCR
Total RNA was extracted from cells using RNeasy Mini Kit spin columns (Qiagen). First strand
cDNA was synthesized using 5X All-In-On MasterMix (MasterMix-LR, Diamed) per manufacturer’s
protocol. Reverse transcriptase real-time polymerase chain reaction (RT-PCR) was carried out on 96-well
plates using iTaq Universal SYBR Green Supermix (BioRad). Concentrations for each sample were
measured using the NanoDrop ND-100 spectrophotometer 119 (NanoDrop Technologies, Wilmington,
DE, USA) and Qubit (Thermo Fischer Scientific, 120 Waltham, MA, USA). The primer sequences were
designed using Primer ExpressTM Software v3.0.1 (ThermoFisher Scientific, Franklin, MA, USA)
(Table 1).
Table 1. List of primers sequences used for reverse transcriptase real-time PCR.
Gene Forward (5′-3′) Reverse (5′-3′)
CCL5 GGTGCCAGCAAGATAACCCT GCTTGCCTGACTTCCTCCTT
MX1 AGGTTCCAGTAGGGCATGTG TTGGAAAGAAGGTGCTTGCT
CCL21 CTGGACAAGACACCATCCCC TGTACTGGGGAGCCGTATCA
IFNγ CTCATGTAAGCCCCCAGAAA GCCCAGTTCCTGCAGAGTAG
ALOX5 ACTTCGCCGACTTTGAGAAA CAAGGGTGACCACAGTGATG
MMP9 GTCTTGTGGAGGCTTTGAGC CAGGGATCTCCCCTCCTTAG
CCL4 GCTAAATCCAGTGGGTGGAA GCTTGCTTCTTTTGGTTTGG
IL-3 GTAGAGACGGGGTTTCACCA GGCACAGGCCTAGAAGTGAG
TLR9 CAGCAGCTCTGCAGTACGTC AAGGCCAGGTAATTGTCACG
IL-1B GGCTGCTGACTTTGAAGGAC CATGGGAAGAAACTGGGAGA
LIMK1 TCTGCAAGTGTTCGCCATAG AGGGAGGCTCTGAAGGAAAG
C1R GTTTTGGCAGGTGGCTCTTG AGGCACAGTGGTTTCCCAAA
MASP2 CCCTGGAGATTGATTCCTCA AAACCCACTGGTCAGTTTCG
OXER1 GAAACCCACCTAGGCCTCTC TTGGAAGGGACAAACTGGAG
TLR3 AGCCTTCAACGACTGATGCT TTTCCAGAGCCGTGCTAAGT
STAT1 GCAGAGACATGCCTTTGTCA GCCACTCAGCTATTGCTTCC
PPP1R12B CCAAGTTGATTCAAGCAGCA GTTCAAGTCCAGGGCAACAT
MX2 AGGTTCCAGTAGGGCATGTG TTGGAAAGAAGGTGCTTGCT
HSH2D CCACGCATGTAGGGAAGTTT AGGGTCAGGGCTGTGTTATG
CCR4 GTACTCCAACCTGGGCAAAA CAGACTGGGTGACAGAGCAA
LT-β AGGAGCCACTTCTCTGGTGA AAAAGACCACAGGCACAACC
IFIT1 CTGTGGTAGGCTCTGCTTCC CCACCACACCCAGCTAAGTT
TGF-β2 GGCAAATAGCCTGGTGTTGT GCTGAGTTGGCATTCTGACA
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2.4. NanoString
Gene expression was assessed using the NanoString PanCancer Pathway Panel (NanoString
Technologies, Seattle, WA, USA) consisting of probes for 770 genes implicated in carcinogenic pathways,
curated from The Cancer Genome Atlas (TCGA) data. All RCC files (direct outputs/raw data from
NanoString runs) were normalized using nSolver analysis software (NanoString Technologies, Seattle,
WA, USA) according to the manufacturer’s protocols (nSolver User Manual). In brief, a normalization
factor was calculated by obtaining the geometric mean of the controls used for each sample and
applied to the raw counts of the nCounter output data to eliminate variability that was unrelated to
the samples. The resulting data were normalized again with the geometric mean of the housekeeping
genes. Normalized data were log2-transformed and exported to Microsoft Excel for analysis.
2.5. Gene Profile and In Silica Analyses
The in silico approach used in our study helped us to support and confirm our findings
(the differentially expressed genes (DEGs) were discovered by NanoString analysis as previously
described). The large, publicly available database Oncomine TM consists of approximately 65 gene
expression datasets and was used to explore the differential expression of our genes to compare HN
cancer with respective normal tissues as well as clinico-pathological parameters. From this database
we used Toruner, Ginos, Cromer, Ye, Peng, Sengupta, Estilo, Kuriakose, and TCGA datasets to evaluate
mRNA expression of the discovered DEGs in normal versus malignant patient samples. In addition,
TCGA Head and Neck dataset (270 patients) was used to evaluate the differences in the DNA copy
numbers between smoker head and neck cancer patients compared with non-smokers with head
and neck cancer. In brief, the parameters were set and the program generated the expression levels
per dataset; analysis was performed, and we finally selected genes that were statistically relevant
to our study. Moreover, we used a cohort of 500 HN squamous cell carcinomas (HNSCC) samples
from the Pan-cancer RNA-seq dataset of the Kaplan–Meier plotter database to analyze the patients’
clinical outcome.
2.6. Network and Pathway Interaction
The Search Tool for the Retrieval of Interacting Genes (STRING v9.1) (https://string-db.org/)
tool was used to investigate the network and interaction between the different WPS deregulated
genes as well as biological function. This is a biological database and web resource of known and
predicted protein–protein interactions. Briefly, we uploaded the obtained gene list and the software
imported protein association knowledge from databases of physical interaction and databases of
curated biological pathway knowledge; the program utilizes computational predictions to generate
maps and connections between different proteins. We used this tool to highlight the importance of the
potential connectivity network of our genes that need to be considered for the full understanding of
the biological phenomena.
2.7. Statistical Analysis
In vitro assays were all performed in triplicates of at least three independent experiments. Results
were shown as means ± SEM. Student’s t-test was used to evaluate the statistical significance. Statistical
analyses were performed using nSolver and GraphPad Prism (version 8.4.3) analysis software. Overall
survival and relapse-free survival (RFS) were performed using the Kaplan–Meier survival analysis
and a p-value < 0.05 was considered significant (log-rank test).
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3. Results
3.1. Identification of Differentially Expressed Genes (DEGs) Deregulated by WPS in HNOE Cells
In order to study the effect of WPS on human HN carcinogenesis, we examined the outcome
of WPS on two human normal oral epithelial, 2N and 11N, which were established in our lab [28].
Our data revealed that treatment of 2N and 11N cell line with 100 µg/mL of WPS solution for 2 days
slightly deregulates cell proliferation and cell cycle progression of both cell lines in comparison with
untreated cells (data not shown). On the other hand, we found that WPS exposure induces EMT,
where both cell lines display a more mesenchymal phenotype in comparison with their matched
unexposed controls (Figure 1). The cells become more elongated in appearance and show a decrease in
cell–cell contact compared with untreated ones (Figure 1).
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Figure 1. Water-pipe smoking (WPS) stimulates epithelial–mesenchymal transition (EMT) of human
normal oral epithelial (HNOE) cell lines, 2N and 11N. We note that treatment for 2 days with 100
µg/mL of WPS solution induces morphological changes from epithelial (control) into a “fibroblast-like”
(mesenchymal) phenotype, which is known as EMT.
Similar to our study, we previously examined the expression of E-cadherin and focal adhesion
kinase (FAK) proteins in cancer cells exposed to WPS [27]. Our data showed loss of E-cadherin
and enhanced expression of FAK proteins in WPS-exposed cells in comparison to unexposed ones;
thus, indicating WPS promotes EMT progression and enhances cell migration as well as invasion
abilities [27]. Furthermore, analysis of the underlying mechanisms revealed that the expression of
phosphorylated Erk1/2 was upregulated in WPS-exposed cells, thus implying that WPS promotes EMT
via Erk1/2 pathways [27,29,30].
Next, gene expression was applied on both cell lines, using the NanoString PanCancer Pathway
Panel consisting of probes for 770 genes implicated in carcinogenic pathways; our data showed that
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out of these genes, 23 were found to be differentially expressed in WPS-exposed versus unexposed 2N
and 11N cells: CCL5, C1R, MMP9, IL-1B, CCL4, MASP2, OXER1, TLR3, STAT1, PPP1R12B, MX1, MX2,
CCL21, IL-3, TLR9, HSH2D, CCR4, IFNγ, LT-β, IFIT1, TGF-β2, ALOX5, and LIMK1 (p < 0.05).
Following the identification of candidate genes, we validated our panel using qRT-PCR analysis.
The set of genes differentially expressed corresponded with the NanoString analysis with twenty-three
(IL-IB, CCL5, C1R, MMP9, LIMK1, CCR4, MASP2, OXER1, TLR3, STAT1, PPP1R12B, MX2, CCL21,
IL-3, TLR9, HSH2D, CCL4, IFNγ, LT-β, IFIT1, TGF-β2, ALOX5 and MX1) upregulated genes by a factor
ranging from 1.58 to 3.8 folds (p < 0.05) (Figure 2).Toxics 2020, 8, x FOR PEER REVIEW 6 of 19 
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Based on the molecular path ays of carcinogenesis, these 23 deregulated genes are directly
involved in the modulation of cell cycle, proliferation, igration, invasion, apoptosis, angiogenesis,
signal transduction, and inflammatory response ( able 2).
Table 2. Genes base t eir f cti l tations.
Mo ecular and Cellular Functions Genes Involv
Cellular Processes
( cle, Proliferation, Migration, Invasion,
poptosis, and Angiogenesis)
CCR4, IL-1B, IL-3, LI 9
Signal Transduction CCL4, CCL21, HSH2D, IFNγ, IFI 2, MX1,MX2, OXER1, P1R12B, ST 1, F-β2, TLR9
Inflammatory Response ALOX5, C1R, CCL4, IF -β
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3.2. Deregulated Genes Are Upregulated in HN Cancer Samples Compared with Normal Tissue
Using the Oncomine database, we herein initially evaluated the mRNA expression levels of the
DEGs discovered in normal tissue versus head and neck tumor samples.
Using the Toruner dataset (20 patient samples), we found that the expression of IFIT1,
(p = 2.76 × 10−8) and ALOX5 (p = 0.0019) genes were high in oral squamous cell carcinoma (OSCC)
compared to normal squamous cells (Figure S1A). The Ginos dataset (54 patient samples) showed
that IL-1B, (p = 1.77 × 10−8), STAT1 (p = 9.25 × 10−11), MX2 (p = 0.22 × 10−8), LT-β (p = 2.43 × 10−6),
C1R (p = 0.005), CCL5 (p = 2.28 × 10−9), MMP9 (p = 7.07 × 10−26), ALOX5 (p = 0.050) and CCL4
(p = 3.20 × 10−15) genes were upregulated in HNSCC compared with the normal buccal mucosa
(Figure S1B). Moreover, Cromer dataset (38 patient samples) reveled that IL-1B (p = 0.002), STAT1
(p = 0.001) and IFNγ (p = 3.46 × 10−4) genes were high in HNSCC compared with normal uvula
tissue (Figure S1C). The dataset (38 patient samples) exhibited IL-1B (p = 2.67 × 10−6), TGF-β2
(p = 2.23 × 10−4), and MMP9 (p = 0.01) genes to be upregulated in tongue squamous cell carcinoma
(SCC) compared with normal tongue tissue (Figure S1D). In addition, the Peng dataset (79 patient
samples) found IL-1B (p = 4.52 × 10−10), IFIT1 (p = 1.27 × 10−17), TGF-β2 (p = 2.23 × 10−4), STAT1
(p = 7.18 × 10−20), MX2 (p = 5.11 × 10−11), OXER1 (122 patient samples, p = 0.045), LT-β (p = 0.004),
CCL21 (122 patients, p = 0.005), C1R (p = 0.005), CCR4 (p = 2.50 × 10−5), HSH2D (p = 2.47 × 10−7),
MASP2 (p = 5.16 × 10−5), PPP1R12B (p = 4.10 × 10−4), CCL5 (122 patients, p = 3.33 × 10−12), MX1
(p = 1.70 × 10−9), and IFNγ (p = 6.82 × 10−13) genes to be over expressed in OSCC compared with
normal oral cavity (Figure S1E). Sengupta dataset (41 patient samples) evaluated that expression of IFIT1
(p = 5.38 × 10−5), CCR4 (p = 0.046), and CCL4 (p = 2.79 × 10−8) genes were increased in nasopharyngeal
carcinoma compared with normal nasopharynx (Figure S1F). Estilo dataset (58 patients) showed STAT1
(p = 1.07 × 10−12), MX2 (p = 4.53 × 10−5), and MX1 (p = 1.31 × 10−10) genes to be highly expressed in
tongue SCC compared with normal tongue tissue (Figure S1G). While IL-3 expression in Kuriakose
dataset (20 patient samples) was predominant in lip and OSCC (20 patients, p = 0.009) (Figure S1H).
Additionally, OXER1 (p = 1.38 × 10−9) expression using TCGA dataset is highly upregulated in HNSCC
(364 patient samples) (Figure S1I).
3.3. Deregulated Genes Are Upregulated in Smoking HN Cancer Patients Compared to Non-Smoker Patients
Next, and to further investigate the association between our discovered DEGs and smoking as
a risk factor of cancer, we investigated the DNA copy numbers of the 22 upregulated DEGs in HN
cancer samples in smoker versus non-smoker HN cancer patients. For this analysis, we used TCGA
HN dataset (270 patients) of the Oncomine database. Interestingly, our results confirmed that, of the 22
genes, 16 were upregulated in smoking HN cancer patients compared to those who had never smoked.
These genes include CCL5, C1R, MMP9, IL-1B, CCL4, OXER1, TLR3, STAT1, PPP1R12B, MX1, MX2,
HSH2D, IFNγ, LT-β, IFIT1, and TGF-β2 (p ≤ 0.05) (Figure S2).
3.4. Deregulated Genes by WPS Have a Direct Impact on HN Cancer Patient’s Prognosis
Subsequently, we explored whether the DEGs induced by WPS in oral epithelial cells could have
an impact on the prognosis of HN cancer patients. To asses this point, we analyzed the association
between the DEGs mRNA expression and patient’s outcome, relapse-free survival (RFS), or overall
survival (OS), using a large HNSCC cohort (n = 500 patients) from the Kaplan–Meier plotter database.
Interestingly, while high expression of ALOX5 (p = 0.0091), IFNγ (p = 0.054), C1R (p = 0.0028),
CCL4 (p = 0.001), MASP2 (p = 0.041), PPP1R12B (p = 0.031), TGF-β2 (p = 0.014), and CCL21 (p = 0.0062)
correlates positively with poor RFS (Figure 3A), expression of TLR9 (p = 0.027), IFIT1 (p = 0.021) and
IL-3 (p = 0.0031) correlates positively with poor OS (Figure 3B).
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Figure 3. (A,B): Relapse-free survival (RFS) in HN cancer patients using the Kaplan–Meier plotter
database, expressed by relapse-free survival (RFS) and overall survival (OS).
3.5. WPS Deregulated Genes Are Mainly Involved in Immune Response and Cytokine/Chemokine
Mediated Pathways
We investigated major gene interactions between top DEGs and possible pathway enrichment.
Interestingly, our results showed a strong interaction with major biological processes including immune
response, cytokine-mediated signaling pathway, and cellular response to cytokine stimulus. Moreover,
the molecular functions shared between the top DEGs were also found to be related to cytokine and
Cysteine-Cysteine Chemokine Receptor (CCR) chemokine binding receptors (Figure 4), (Table 3).
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Figure 4. Protein interaction analysis of the WPS upregulated and differentially expressed genes using
the Search Tool for the Retrieval of Interacting Genes (STRING v9.1). Enriched biological process and
molecular functions of those proteins are included.
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Table 3. Functional annotations of the differentially expressed genes.
Molecular Function (GO)
Go-Term Description Count in Gene Set False Discovery Rate
GO:0005126 Cytokine receptor binding 10 of 272 6.46 × 10−11
GO:0005125 Cytokine activity 8 of 216 6.87 × 10−9
GO:0048020 CCR chemokine receptor binding 4 of 41 5.61 × 10−6
GO:0031730 CCR5 chemokine receptor binding 3 of 7 5.61 × 10−6
GO:0005149 Interlukin-1 receptor binding 3 of 18 3.85 × 10−5
Biological Process
Go-Term Description Count in Gene Set False Discovery Rate
GO:0006955 Immune response 18 of 1560 1.54 × 10−13
GO:0002376 Immune system process 20 of 2370 1.54 × 10−13
GO:0019221 Cytokine-mediated signaling pathway 14 of 655 3.65 × 10−13
GO:0071345 Cellular response to cytokine stimulus 15 of 953 1.22 × 10−12
GO:0006952 Defense response 16 of 1234 1.22 × 10−12
4. Discussion
This investigation, to the best of our knowledge, is the first cancer genes profiling study on
the effects of WPS exposure on human normal oral epithelial cells. Previously, our group has
revealed that WPS can play an important role in the initiation and progression of human oral cancer,
which represents the majority of HN cancer cases [24]. In this study, we found that WPS can induce
EMT, which is the hallmark of cancer progression in human normal oral epithelial cells by loss of
E-cadherin and upregulation of FAK protein as well as Erk1/2 pathways as previously demonstrated
in our study [27,29,30]. More importantly, we used a NanoString nCounter PanCancer Pathways
panel of 770 gene transcripts distributed in 13 biological pathways to determine gene targets of WPS
exposure in human normal oral epithelial (HNOE) cells. Thus, we identified significant changes in the
expression of 23 genes, with one gene being down-regulated and twenty-two being upregulated. In our
investigation, we confirmed, both by qRT-PCR as well as the Oncomine TM database, the deregulation
of the newly identified genes as targets for WPS exposure in oral cells. We also analyzed the prognostic
effect of the WPS-induced deregulated genes on HNSCC survival and prognosis using Pan-cancer
RNA-seq dataset of the Kaplan–Meier plotter database. More significantly, our study points out
that these genes are discovered for the first time as targets of WPS exposure in human normal oral
epithelial cells. The uncovered genes encode for proteins that are known for regulating cell cycle,
proliferation, migration, invasion, apoptosis, angiogenesis, signal transduction, and inflammatory
response. Therefore, the newly identified genes can plausibly play a role in the neoplastic transformation
of normal oral epithelial cells and consequently HN cancer initiation in general.
Of the nine differentially expressed genes, four (CCL5, CCL21, CCL4, and CCR4) belong to the family
of chemokines. Elevated CCL5 levels are significantly associated with oral cancer progression [31],
relapse, and/or metastasis [32,33], as well as drug resistance [34], indicating its fundamental role
in oral carcinogenesis [35]. Our results are concordant, suggesting CCL5 association with oral
cancer progression upon WPS intake. Moreover, CCL5 is capable of upregulating the release of
MMP-9 [36], a matrix-metalloproteinase that was also identified in our study. CCL5 enhances oral
cancer cell migration through the increase in MMP-9 production [31]. Earlier studies have shown that
overexpression of MMP9 is observed in oral cancer [37] and is associated with a poor disease-free
survival (DFS) [38]. Similar data were observed in this study. Interestingly, ALOX5 acts as a mediator of
invasion via MMP-9 induction [39]. ALOX5 expression is known to be involved in carcinogenesis [39]
and is also involved in chronic obstructive pulmonary disease (COPD) [40]. Additionally, ALOX5
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genotype was found to be linked with asthma and poorer lung function [41], while its expression
in mice models showed increase in inflammation, oxidative stress as well as emphysema caused
by cigarette smoke [42], indicating its possible involvement in oral cancer upon exposure to smoke
from WPS. Although a previous study has shown an association between ALOX5 with poor asthma
controls [41], there are no studies indicating association of ALOX5 with RFS; we herein show for the
first time that ALOX5 is associated with shorter RFS.
Similar to CCL5, CCL4 has analogous role in cancer progression; CCL4 enhances susceptibility
to oral cancer [43]. It has been shown that CCL4 stimulates VEGF-C expression by activating
the JAK2/STAT3 signaling pathway, which is frequently linked with oral cancer cell proliferation,
invasion, and angiogenesis [44]. A recent investigation showed that smoking along with CCL4 gene
polymorphisms can increase risk of oral cancer [43]. Likewise, we found that WPS smoking can
augment CCL4 expression resulting in enhanced inflammatory response, thus promoting tumor
development and progression. Similar to our data, CCL4 expression is linked with poor prognosis in
cancer [45]. On the other hand, cigarette smoking has been shown to increase blood and bronchoalveolar
lavage fluid levels of the CCR7 ligands CCL19 and CCL21 [46], thereby contributing to migration
of lung cancer cells [47]. Additionally, previous research has considered CCL21 in oral cancer as a
candidate marker for unfavorable outcome [48]. In this study, we confirm that CCL21 is a target of
WPS exposure in oral epithelial cells, implying its possible role in cell transformation and therefore HN
carcinogenesis. Concordant to our data, recently it has been pointed out that CCL21/CCR7 is linked
with cancer recurrence, smoking, and poor prognosis in HN cancer [49,50]. In this regard, chemokine
receptors are G protein-coupled receptors and are involved in the onset and progression of several
solid tumors [51–53]. Concordant to our data, several investigations reported CCR4 to play a role in
lymph node metastasis of HNSCC as well as its progression and recurrence [50,54]. Moreover, we also
identified upregulated expression of G protein coupled OXER1 in HNSCC. OXER1 has been reported
to be upregulated in both prostate cancer cells as well as tumor tissues [55]. However, although, no
direct role of OXER1 has been studied in HNSCC, upregulation of OXER1 in human papillomavirus
(HPV)-positive tumors has been previously reported [56]. Since HPV is found to play a role in the
onset and progression of HN as well as oral cancers [28,57,58], we suggest a link between OXER1
expression and HN as well as oral cancers.
Moreover, in this study, of the 23 genes, 4 (TLR3, TLR9, C1R and MASP-2) of them are involved
in innate immune system. We reveal that TLR3 and TLR9 are upregulated in WPS-exposed oral
epithelial cells. It has been demonstrated that HN cancer cell lines as well as OSCC tissue samples
express TLR3 thereby enhancing the expression levels NF-κB and its regulated oncogene, c-myc, thus
inciting cellular proliferation and migration, which is significantly associated with poorly differentiated
tumor cells and perineural invasion [59–62]. Similar to data obtained in this study, upregulated
expression of TLR9 in HNSCC as well OSCC was found to promote tumor cell invasion, proliferation
as well as migration by enhancing MMP-2 expression [63–66]. Although C1R is known to regulate
the complement pathway of the innate immune system, in this study, we found upregulated CIR
expression in HNSCC. This is in concordance with a previous study that correlated the expression of
C1R in cutaneous SCC (cSCC) with tumor progression, cell proliferation, and migration [67,68]. Since
cSCC lesions frequently develop in the HN region [69], our data correlate with this finding. Although,
the prognostic relevance of C1R has not been studied in cancer; however, it is associated with tumor
progression and migration [67,68], hence our data suggest a significant correlation between C1R and
shorter RFS. Furthermore, our data implicate the other member of the complement pathway, MASP-2
gene, which is upregulated in oral epithelial cells exposed to WPS. MASP-2 produced in hepatocytes is
involved in innate response, and its promoter is regulated by cytokines (interleukins and TGF-β) or
transcription factor (STAT) [70]; our study found both cytokines and STAT to be expressed in WPS
exposed HNOE cells. Previous studies have found an association between MASP-2 expression and
cancer [71–73]; MASP-2 expression significantly correlates with late clinical stage and nodal metastasis,
thus indicating its role in cancer progression and aggressive tumor behavior in esophageal SCC [71].
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Moreover, MASP-2 is significantly associated with recurrence and poor survival of colorectal as well as
ovarian cancers [72,73], thus suggesting a link with poor RFS, similar to data found in this study.
The pro-inflammatory cytokine, IL-1B, is elevated in HNSCC including oral cancer [74,75].
Furthermore, similar to our data, an earlier study demonstrated the upregulation of IL-1B in tobacco
and betel quid-mediated OSCC; IL-1B promotes proliferation of dysplasia of oral cells, thus triggering
oncogenic cytokines as promoters of tumor aggressiveness [76]. On the other hand, cytokine IL-3, is a
selective growth factor that stimulates tumor angiogenesis [77]. However, although the role of IL-3 in
COPD as well as cigarette smoking is not well defined, IL-3 levels were previously detected in SCC [78].
We herein show presence of IL-3 in oral epithelial cells under the effect of WPS, thus indicating its
role in oral cancer progression. Although data have shown strong correlation between IL-3 and poor
survival in acute myeloid leukemia [79], research on the role of IL-3 in OSCC is scarce. Interestingly,
a recent study by Almeida et al. (2019) showed an association between IL-4, IL-6, IL-8, IL-10, IL-12,
and IL-13 and poor survival in OSCC [80]. In this study, we found IL-3 to significantly correlate with
poor overall survival, which requires further investigation. On the other hand, transforming growth
factor (TGF), a cytokine, is involved in promoting cellular invasion as well as angiogenesis in OSCC
cells [81,82]. Our data revealed the presence of TGF-β2 in WPS-exposed oral epithelial cells as well as
in HNSCC; previous studies have indicated the presence of TGF-β2 in cancer associated fibroblasts
from OSCC [83] as well as in SCC cell lines [84]. Similar to our data, elevated TGF expression was
significantly associated with shorter OS, RFS, and DFS in patients with OSCC [85]. The other type
of cytokine identified in this study is IFNγ. In oral epithelial cells, a loss of IFNγ expression may
be caused by the IFN-γ promoter methylation as a plausible underlying mechanism for oral cancer
progression [86]. Furthermore, and in concordance with our data, low IFNγ levels are associated with
poor prognosis in HNSCC including oral [87,88]. The other cytokine, LT-β, was also identified in this
study; LT-β has been shown to correlate with human oral cancer [89], and additionally, it activates the
NIK-IKKa-RELB/NF-κB2 pathway to stimulate HNSCC cell migration [90,91]. While STAT1 has a dual
role in HNSCC [92–94], we report upregulation of STAT1 in OSCC as well as HNSCC, as reported
previously [92], suggesting an oncogenic role of STAT1 in the pathogenesis of HNSCC.
On the other hand, we report the upregulation of an interferon-stimulated gene, IFIT-1,
in WPS-exposed HNOE cells. In this context, a previous study showed that over-expression of
IFIT1 in OSCC cells promote tumor growth and metastasis by activating EGFR signaling [95]. Research
in OSCC has shown a distinct correlation between elevated IFIT1 expression with T-stage, lymph node
metastasis, lymphovascular, perineural invasion, as well as poor overall survival in OSCC patients [95].
Moreover, increased IFIT1 expression in OSCC cells enhance resistance to several therapeutic agents
(5-FU, carboplatin, cisplatin, ganetespib, and oxaliplatin) [96,97], thus indicating its role in poor RFS,
which is similar to data obtained in our study. We identified the interferon-related gene, MXI along
with its paralogue MX2. MX1 has a contradictory role in cancer; in one study, MX1 is upregulated
in OSCC [98], but nevertheless, it is hyper methylated in HN cancer [99]. However, in our study,
we found that exposure to WPS smoke in oral epithelial cells induced expression of MX1, indicating its
possible oncogenic role in oral cancer.
Interestingly, we discovered two genes (HSH2D and PPP1R12B) in our cohort that were not
previously reported, as possible players in OSCC or HNSCC. Traditionally, HSH2D has a role in T-cell
activation and is a downstream target of CD28 costimulatory signaling pathway [100]. A previous
study has reported loss of CD28 on T-cell in HNSCC [101]; thus, we postulate a role of HSH2D activation
in HNSCC. Moreover, PPP1R12B, also known as MYPT2, is a subunit of MYPT [102]. Although
no direct role of MYPT2 is implicated in cancer, MYPT is found to be involved in cancer [103,104],
indicating a plausible role for MYPT2 in HNSCC. We found PPP1R12B to be associated with poor RFS.
However, studies have shown MYPT to correlate significantly with drug resistance and poor prognosis
in human carcinomas [103,104], thus postulating a plausible role of PPP1R12B in drug resistance and
poor prognosis in OSCC or HNSCC.
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An earlier study by our group show clearly that WPS stimulate cell invasion of human breast
cancer cells [27]. While several investigations have shown a significant correlation between smoking
and the onset/progression of oral cancer [27,105–108]. In addition, it has been revealed that cigarette
smoking can enhance EMT of several human carcinoma cells [29,109–112]. Thus, it is apparent that
smoking is an important etiological factor in the onset of numerous human cancers inducing lung,
HN (especially oral) as well as breast [27,105,113–115]. Nevertheless, based on the number and level
of toxicants and the duration of smoking session, it can be assumed that WPS is more harmful with
regards to the development and progression of human cancers as well as cancer-related deaths in
comparison with cigarette smoking.
5. Conclusions
We reveal for the first time, that WPS can induce EMT in human normal oral epithelial cells,
which is accompanied by the deregulation of a set of genes related to oncogenesis. Thus, WPS can
promote HN cancer initiation and/or progression mainly due to its effect on key regulatory genes of
carcinogenesis that have a direct impact on HN cancer patients’ outcome. Nevertheless, further studies
are needed to elucidate the expression of different proteins involved in EMT as well as to understand
the full mechanism by which WPS can induce HN carcinogenesis.
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